ALSO NOTED: Abbott stent gets review; Studies ease finasteride fears; The Pill cuts cancer risk;

> And in other stent news, the FDA plans to schedule an advisory committee meeting to discuss Abbott Laboratories' Xience drug-coated version, already sold overseas. Report

> New studies may ease fears of finasteride, a generic drug that's effective in preventing prostate cancer--but until now was thought to promote fast-growing tumors in those patients who did develop cancer. Release

> The Pill may actually cut cancer risk--up to 12 percent, in fact--provided women don't take it for longer than eight years, according to a new study published in the British Medical Journal. Report

> Natco Pharma has launched a generic version of Lenalid, used to treat Myelo Dysplastic Syndrome. Report

> Venture capitalists are betting big on nanotechnology. Report

And Finally... Pharma companies may be experts at some technologies, but their online advertising is mired in the Internet dark ages. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.